Two Years On The Market And Only A 7% Volume Share – J&J Numbers Reveal Infliximab Struggle For US Biosimilars
Value-wise, Johnson & Johnson’s sales of the Remicade original in the US fell by around a fifth last year with two biosimilars on the market, the originator has just reported. However, thanks in part to what it described as “increased discounts,” J&J was able to retain more than nine-tenths of the infliximab market by volume.
You may also be interested in...
More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.
Metastatic castration-sensitive prostate cancer could see a marketing race following positive top-line clinical data for Janssen’s apalutamide in the Phase III TITAN study.
Generics of Janssen’s Zytiga (abiraterone acetate) blockbuster could enter the US market imminently, after a US Court of Appeals refused twice in quick succession to grant the originator injunctions blocking such launches.